Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for Type 2 diabetes
- 20 March 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 16 (4) , 533-545
Abstract
Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. It is the first in this new class of antihyperglycaemic agents to gain regulatory approval for the treatment of Type 2 diabetes, both as a monotherapy and for use in combination with metformin or a thiazolidinedione. In clinical trials of < or = 1-year duration, sitagliptin improves glycaemic control by reducing both fasting and postprandial glucose concentrations, leading to clinically meaningful reductions in glycosylated haemoglobin levels. It is safe and well tolerated, with a side-effect profile that is similar to that of the placebo, a low incidence of hypoglycaemia and body weight neutrality. Further clinical experience with sitagliptin will reveal its long-term durability, safety and efficacy.Keywords
This publication has 47 references indexed in Scilit:
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapyDiabetologia, 2006
- Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspectiveMetabolism, 2006
- Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetesThe International Journal of Biochemistry & Cell Biology, 2006
- Beta- and Alpha-Cell Dysfunction in Type 2 DiabetesHormone and Metabolic Research, 2004
- Glucagon-like Peptide 1 (GLP-1) in the Treatment of DiabetesHormone and Metabolic Research, 2004
- On the Physiology of GIP and GLP-1Hormone and Metabolic Research, 2004
- Global Prevalence of DiabetesDiabetes Care, 2004
- β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 DiabetesDiabetes, 2003
- Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy SubjectsDiabetes, 1995